{"id":"NCT01154127","sponsor":"Novartis Pharmaceuticals","briefTitle":"Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50Âµg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2010-06-30","resultsPosted":"2012-05-07","lastUpdate":"2012-05-07"},"enrollment":108,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"NVA237","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NVA237 followed by Placebo","type":"EXPERIMENTAL"},{"label":"Placebo followed by NVA237","type":"EXPERIMENTAL"}],"summary":"The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD. This study is designed to look at how well NVA237 improves the ability to exercise in patients with moderate to severe COPD.","primaryOutcome":{"measure":"Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment","timeFrame":"Day 21","effectByArm":[{"arm":"NVA237","deltaMin":505.63,"sd":null},{"arm":"Placebo","deltaMin":416.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":10,"countries":["United States","Germany","Italy","Romania","United Kingdom"]},"refs":{"pmids":["22973092"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":102},"commonTop":[]}}